

**APA751Ra01 100µg**  
**Active Programmed Cell Death Protein 1 (PD1)**  
**Organism Species: *Rattus norvegicus (Rat)***  
***Instruction manual***

FOR RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

13th Edition (Revised in Aug, 2023)

## **[ PROPERTIES ]**

**Source:** Prokaryotic expression.

**Host:** *E. coli*

**Residues:** Pro39~Ser266

**Tags:** N-terminal His and GST Tag

**Purity:** >90%

**Endotoxin Level:** <1.0EU per 1µg (determined by the LAL method).

**Buffer Formulation:** PBS, pH7.4, containing 0.01% SKL, 5%Trehalose .

**Original Concentration:** 200µg/mL

**Applications:** Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 6.0

**Predicted Molecular Mass:** 55.0kDa

**Accurate Molecular Mass:** 55kDa as determined by SDS-PAGE reducing conditions.

## **[ USAGE ]**

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## **[ STORAGE AND STABILITY ]**

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

## [ **SEQUENCE** ]

```
PT WLTVSEGANA TFTCSFSNWS
EDLKLNWYRL SPSNQTEKQA AFCNGYSQPV RDARFQIVQL PNGHDFHMINI LDARRNDSGI
YLCGAISLPP KAQIKESPGA ELVVTERILE TPTRYPRPSP KPEGQFQGLV IVIMSVLVGI
PVLLLLAWAL AAF CSTGMSE AREAGRKEDP PKEAHA AAPV PSVAYEELDF QGREKTPEPA
PCVHTEYATI VFTEGLDASA IGRRGS
```

## [ **ACTIVITY** ]

PD-1 (Programmed Death-1 receptor), also known as CD279, is a receptor expressed on T cells responsible for modulating T cell activation. Like CTLA-4, PD-1 is classified as an immune checkpoint inhibitory receptor. When PD-1 protein binds to PD-L1, it initiates a negative signaling cascade inhibiting activation of T cells. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. Normally, PD-1 helps keep T cells from attacking other cells in the body. However, many cancers take advantage of this by expressing high amounts of PD-L1 allowing cancer cells to evade the body's own immune response. Blocking the PD-1:PD-L1 interaction has proven successful in treating many different cancer types. A functional binding ELISA assay was conducted to detect the interaction of recombinant rat PD1 and recombinant human CTLA4. Briefly, PD1 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100  $\mu$ l were then transferred to CTLA4-coated microtiter wells and incubated for 1h at 37°C. Wells were washed with PBST and incubated for 1h with anti-PD1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37°C, wells were aspirated and washed 5 times. With the addition of substrate

solution, wells were incubated 15-25 minutes at 37 °C . Finally, add 50 µL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant rat PD1 and recombinant human CTLA4 was shown in Figure 1, the EC50 for this effect is 0.04 ug/mL.





Figure 1. The binding activity of recombinant rat PD1 and recombinant human CTLA4

**[ IDENTIFICATION ]**



**Figure 2. SDS-PAGE**

**Sample: Active recombinant PD1, Rat**

**[ IMPORTANT NOTE ]**

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.